ArticleRadiation research2011
Medical countermeasures for platelet regeneration after radiation exposure. Report of a workshop and guided discussion sponsored by the National Institute of Allergy and Infectious Diseases, Bethesda, MD, March 22–23, 2010.
Article in Radiation research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Multiphasic blood transcriptomic signatures of radioprotection by BIO 300, a synthetic genistein nanosuspension, in a nonhuman primate model of acute radiation syndrome.Journal of translational medicine · 2026Article
- Mature megakaryocytes acquire immune characteristics in a mouse model of aplastic anemia.Blood advances · 2025Article
- Genetic architecture of the acute and persistent immune cell response after radiation exposure.Cell genomics · 2023Article
- Benefits and challenges of in vivo EPR nail biodosimetry in a second tier of medical triage in response to a large radiation event.Radiation protection dosimetry · 2023Review
- Scientific research and product development in the United States to address injuries from a radiation public health emergency.Journal of radiation research · 2021Article
- Repurposing Pharmaceuticals Previously Approved by Regulatory Agencies to Medically Counter Injuries Arising Either Early or Late Following Radiation Exposure.Frontiers in pharmacology · 2021Review
- Fibrinogen-Coated Albumin Nanospheres Prevent Thrombocytopenia-Related Bleeding.Radiation research · 2020Article
- Challenges and Benefits of Repurposing Products for Use during a Radiation Public Health Emergency: Lessons Learned from Biological Threats and other Disease Treatments.Radiation research · 2018Article
- 2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia.Blood advances · 2018Article
- Understanding the Pathophysiology and Challenges of Development of Medical Countermeasures for Radiation-Induced Vascular/Endothelial Cell Injuries: Report of a NIAID Workshop, August 20, 2015.Radiation research · 2016Article
- Recombinant human thrombopoietin promotes hematopoietic reconstruction after severe whole body irradiation.Scientific reports · 2015Article
- Road blocks in making platelets for transfusion.Journal of thrombosis and haemostasis : JTH · 2015Review
- No irradiation required: The future of humanized immune system modeling in murine hosts.Chimerism · 2015Review
- Space Radiation: The Number One Risk to Astronaut Health beyond Low Earth Orbit.Life (Basel, Switzerland) · 2014Review
- Acute exposure to high dose γ-radiation results in transient activation of bone lining cells.Bone · 2013Article
- Potential for a pluripotent adult stem cell treatment for acute radiation sickness.World journal of experimental medicine · 2012Article
- Animal models and medical countermeasures development for radiation-induced lung damage: report from an NIAID Workshop.Radiation research · 2012Article
- Development and licensure of medical countermeasures to treat lung damage resulting from a radiological or nuclear incident.Radiation research · 2012Article
- Development and licensure of medical countermeasures for platelet regeneration after radiation exposure.Radiation research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
The events of September 11, 2001 and their aftermath increased awareness of the need to develop medical countermeasures (MCMs) to treat potential health consequences of a radiation accident or deliberate attack. The medical effects of lethal exposures to ionizing radiation have been well described and affect multiple organ systems. To date, much of the research to develop treatments for mitigation of radiation-induced hematopoietic damage has focused on amelioration of radiation-induced neutropenia, which has long been considered to be the primary factor in determining survival after an unintentional radiation exposure. Consistent with historical data, recent studies have highlighted the role that radiation-induced thrombocytopenia plays in radiation mortality, yet development of MCMs to mitigate radiation damage to the megakaryocyte lineage has lagged behind anti-neutropenia approaches. To address this gap and to foster research in the area of platelet regeneration after radiation exposure, the National Institute of Allergy and Infectious Diseases (NIAID) sponsored a workshop on March 22-23, 2010 to encourage collaborations between NIAID program awardees and companies developing pro-platelet approaches. NIAID also organized an informal, open discussion between academic investigators, product development contractors, and representatives from the U.S. Food and Drug Administration (FDA) and other relevant government agencies about drug development toward FDA licensure of products for an acute radiation syndrome indication. Specific emphasis was placed on the challenges of product licensure for radiation/nuclear MCMs using current FDA regulations (21 CFR Parts 314 and 601) and on the importance of animal efficacy model development, design of pivotal protocols, and standardization of irradiation and animal supportive care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.